233 related articles for article (PubMed ID: 807649)
1. Activation of the alternative (properdin) pathway by divalent cations.
Lew FT; Yukiyama Y; Waks HS; Osler AG
J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
[TBL] [Abstract][Full Text] [Related]
2. Schistosoma mansoni: the role of the complement C3-activating system in the cercaricidal action of normal serum.
Machado AJ; Gazzinelli G; Pellegrino J; Dias de Silva W
Exp Parasitol; 1975 Aug; 38(1):20-9. PubMed ID: 807484
[No Abstract] [Full Text] [Related]
3. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
4. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.
Vogt W; Dieminger L; Lynen R; Schmidt G
Hoppe Seylers Z Physiol Chem; 1974 Feb; 355(2):171-83. PubMed ID: 4215726
[No Abstract] [Full Text] [Related]
5. Changes in the immunochemical properties of highly purified properdin in human serum.
Minta JO
J Immunol; 1975 Apr; 114(4):1415-21. PubMed ID: 123262
[TBL] [Abstract][Full Text] [Related]
6. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
7. Studies on the properdin system: isolation of a heat-labile factor from guinea pig serum related to a human glycine rich beta-glycoprotein (GBG or factor B).
Brade V; Cook CT; Shin HS; Mayer MM
J Immunol; 1972 Dec; 109(6):1174-81. PubMed ID: 4628703
[No Abstract] [Full Text] [Related]
8. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
Des Prez RM; Bryan CS; Hawiger J; Colley DG
Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
[TBL] [Abstract][Full Text] [Related]
9. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
Yukiyama Y; Lew FT; Waks HS; Osler AG
J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
[TBL] [Abstract][Full Text] [Related]
10. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
11. The alternative pathway of complement activation.
Götze O; Müller-Eberhard HJ
Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
[No Abstract] [Full Text] [Related]
12. In vivo abrogation of serum C3 and C5 by administration of cobra venom factor and heterologous anti-C3.
Drake WP; Pokorney DR; Mardiney MR
J Immunol Methods; 1974 Dec; 6(1-2):61-72. PubMed ID: 4215835
[No Abstract] [Full Text] [Related]
13. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
14. Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway.
May JE; Frank MM
J Immunol; 1973 Dec; 111(6):1668-76. PubMed ID: 4750863
[No Abstract] [Full Text] [Related]
15. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
Schreiber RD; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
[TBL] [Abstract][Full Text] [Related]
16. Studies of the alternate pathway in chelated serum.
Forsgren A; Mclean RH; Michael AF; Quie PG
J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
[TBL] [Abstract][Full Text] [Related]
17. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
18. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
19. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
Fearon DT; Austen KF
J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
[TBL] [Abstract][Full Text] [Related]
20. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
Brade V; Nicholson A; Bitter-Suermann D; Hadding U
J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
